Investigating G protein signalling bias at the glucagon‐like peptide‐1 receptor in yeast

E-ISSN： 1476-5381|171|15|3651-3665

ISSN： 0007-1188

Source： BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol.171, Iss.15, 2014-08, pp. : 3651-3665

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Effects of gastric inhibitory polypeptide, glucagon‐like peptide‐1 and glucagon‐like peptide‐1 receptor agonists on Bone Cell Metabolism

BASIC AND CLINICAL PHARMACOLOGY & TOXICOLOGY (ELECTRONIC), Vol. 122, Iss. 1, 2018-01 ,pp. : 25-37

John Wiley & Sons Inc

Access to resources Recommend Favorite

GLP‐1 and cardiovascular disease in diabetes

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 172, Iss. 3, 2015-02 ,pp. : 721-736

John Wiley & Sons Inc

Access to resources Recommend Favorite

Xenopus‐derived glucagon‐like peptide‐1 and polyethylene‐glycosylated glucagon‐like peptide‐1 receptor agonists: long‐acting hypoglycaemic and insulinotropic activities with potential therapeutic utilities

BRITISH JOURNAL OF PHARMACOLOGY (ELECTRONIC), Vol. 175, Iss. 3, 2018-02 ,pp. : 544-557

John Wiley & Sons Inc

Access to resources Recommend Favorite

Early use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in Type 2 diabetes

By Ross Stuart A. Ballantine Jane

Current Medical Research and Opinion, Vol. 29, Iss. 12, 2013-12 ,pp. : 1617-1626

Informa Healthcare

Access to resources Recommend Favorite

Glucagon‐like peptide 1 receptor agonists and cardiovascular risk in type 2 diabetes: a clinical perspective

DIABETES OBESITY & METABOLISM (ELECTRONIC), Vol. 17, Iss. 4, 2015-04 ,pp. : 335-342

John Wiley & Sons Inc

Access to resources Recommend Favorite